RxDoctor Payments Data

Edet Bassey, MD

Internal Medicine · Columbus, GANPI 1336123181

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 48 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Merck$192
  • Novo Nordisk$115
  • Lilly USA, LLC$69
  • GSK$64
  • Abbott$59
  • plus $319 from 13 others

What the payments were for

  • Food & beverage$1,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$41,490
Medicare patients
79
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide271$359,270
FarxigaDapagliflozin Propanediol84$101,979
RybelsusSemaglutide55$91,820
JanuviaSitagliptin Phosphate85$88,353
EliquisApixaban98$86,300
LinzessLinaclotide88$72,869
JardianceEmpagliflozin57$64,062
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$57,688
EntrestoSacubitril/Valsartan29$29,757
MounjaroTirzepatide24$26,197
TradjentaLinagliptin24$24,522
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,354
Tresiba Flextouch U-100Insulin Degludec41$19,321
Combivent RespimatIpratropium/Albuterol Sulfate25$16,869
XareltoRivaroxaban19$14,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$115$451,090326 claims
AstraZenecaFarxiga, Breztri Aerosphere$398$126,333118 claims
MerckJanuvia, Belsomra$192$93,38296 claims
PfizerEliquis$29$86,30098 claims
AbbVieLinzess$17$72,86988 claims
GSKTrelegy Ellipta$64$57,68873 claims
Lilly USA, LLCMounjaro, Trulicity$69$37,80036 claims
NovartisEntresto$34$29,75729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →